Moderate

Pancreatic cystic lesions — evaluation & surveillance

Pancreatic cyst · Gastroenterology
Physician-written · Verified by three sets of doctors · Reviewed November 2026

Bedside summary

Increasingly found incidentally; management separates benign serous cysts from mucinous (IPMN, MCN) lesions with malignant potential. Worrisome/high-risk features direct EUS, resection or structured surveillance.

Red flags

  • Obstructive jaundice
  • Enhancing mural nodule or solid component
  • Main pancreatic duct dilatation ≥10 mm
  • New-onset diabetes or weight loss
  • Rapid cyst growth

Assessment

Differential diagnosis

  • Intraductal papillary mucinous neoplasm (IPMN, main vs branch duct)
  • Mucinous cystic neoplasm (MCN)
  • Serous cystadenoma (benign)
  • Pseudocyst (post-pancreatitis)
  • Cystic degeneration of solid tumour (NET, adenocarcinoma)
  • Solid pseudopapillary neoplasm

Investigations

  • Pancreatic-protocol MRI/MRCP (characterise, ductal communication)
  • Contrast CT if MRI unavailable
  • EUS with fine-needle aspiration (cyst fluid CEA, amylase, cytology, molecular)
  • CA19-9 if concern
  • Review prior imaging for growth

Management

  • Characterise the cyst with MRI/MRCP and determine ductal communication and morphology
  • Identify high-risk stigmata: obstructive jaundice, enhancing mural nodule ≥5 mm, main duct ≥10 mm
  • Identify worrisome features: size ≥3 cm, thickened walls, non-enhancing nodule, duct 5–9 mm, abrupt duct change, lymphadenopathy, raised CA19-9
  • Exclude pseudocyst by history (prior pancreatitis) and fluid amylase
  • Perform EUS-FNA where features are worrisome or diagnosis unclear (high cyst CEA suggests mucinous)
  • Refer lesions with high-risk stigmata or main-duct IPMN for surgical resection assessment
  • Enter branch-duct IPMN/MCN without worrisome features into size-based surveillance
  • Surveillance interval by size: smaller cysts less frequently, larger cysts more frequently
  • Surgically manage mucinous cystic neoplasms in surgically fit patients
  • Escalate to EUS/resection if new worrisome features or growth develop
  • Discuss all concerning lesions at a pancreatic MDT

Drugs & doses

No specific pharmacotherapy — management is surveillance versus surgery

Disposition

Pancreatic MDT; surgical referral for high-risk lesions, structured radiology surveillance otherwise.

Complications & pitfalls

  • Progression to pancreatic adenocarcinoma (mucinous lesions)
  • Acute pancreatitis from ductal obstruction
  • Surgical morbidity if resected
  • Missed malignancy with inadequate follow-up

Exam pearls

  • Serous cystadenomas are benign; mucinous lesions (IPMN, MCN) carry malignant potential and drive management
  • Main-duct IPMN has high malignant potential and usually warrants resection in fit patients
  • High cyst-fluid CEA suggests a mucinous lesion; high amylase suggests ductal communication/pseudocyst
  • A prior episode of pancreatitis makes a pseudocyst far more likely than a neoplasm

Disclaimer: Educational decision support for qualified clinicians and students — not a substitute for clinical judgement, local protocols or a full drug reference. Confirm every dose and contraindication against your formulary before prescribing.